Abstract:Breast carcinoma is the leading factor in women's cancer-related fatalities. Due to its numerous inherent molecular subtypes, breast cancer is an extremely diverse illness. The human epidermal growth factor receptor 2 (HER2) positive subtypes stands out among these subtypes as being especially prone to cancer development and illness recurrence. The regulation of embryonic stem cells' pluripotency and self-renewal is carried out by the SALL4 (Spalt-like transcription factor 4) family member. Numerous molecular pathways operating at the transcriptional, post-transcriptional, and epigenomic levels regulate the expression of SALL4. Many transcription factors control the expression of SALL4, with STAT3 being the primary regulator in hepatocellular carcinoma (HCC) and breast carcinoma. Moreover, this oncogene has been connected to a number of cellular functions, including invasion, apoptosis, proliferation, and resistance to therapy. Reduced patient survival rates and a worse prognosis have been linked to higher levels of SALL4. In order to target the undruggable SALL4 that is overexpressed in breast carcinoma, we investigated the prognostic levels of SALL4 in breast carcinoma and its interaction with various related proteins. Using TIMER 2.0 analysis, the expression pattern of SALL4 was investigated across all TCGA datasets. The research revealed that SALL4 expression was elevated in various cancers. The UALCAN findings demonstrated that SALL4 was overexpressed in all tumor samples including breast cancer especially TNBC (Triple negative breast cancer). The web-based ENRICHR program was used for gene ontology analysis that revealed SALL4 was actively involved in the development of the nervous system, positive regulation of stem cell proliferation, regulation of stem cell proliferation, regulation of the activin receptor signaling pathway, regulation of transcription using DNA templates, miRNA metabolic processes, and regulation of transcription by RNA Polymerase I. Using the STRING database, we analyzed the interaction and involvement of SALL4 with other abruptly activated proteins and used Cytoscape 3.8.0 for visualization. Additionally, using bc-GenExMiner, we studied the impact of SALL4 on pathways abruptly activated in different breast cancer subtypes that revealed SALL4 was highly correlated with WNT2B, NOTCH4, AKT3, and PIK3CA. Furthermore, to target SALL4, we evaluated and analyzed the impact of CLP and its analogues, revealing promising outcomes.

SALL4: an emerging cancer biomarker and target.

The new advance of SALL4 in cancer: Function, regulation, and implication

Sall4 is A New Target in Endometrial Cancer

The Invasion and Metastasis of Colon Adenocarcinoma (COAD) Induced by SALL4

SALL 4 is Silenced in most Adult Tissues , but is Aberrantly Expressed in Cancers Including Hematologic Malignancies

A SALL4/MLL/HOXA9 Pathway in Murine and Human Myeloid Leukemogenesis.

Sall4, a Stem Cell Factor, Promotes Chemoresistance by Regulates the Side Population Cell Phenotype.

The Next New Target in Leukemia: the Embryonic Stem Cell Gene SALL4.

SALL4 and Its Clinical Application Value in Non-Germ Cell Tumors

SALL4, a Novel Marker for Human Gastric Carcinogenesis and Metastasis.

Leukemic Survival Factor Sall4 Contributes to Defective Dna Damage Repair

Constitutive Expression of SALL4B in Mice Confers Properties of Leukemic Stem Cells to Committed Hematopoietic Progenitors.

Effect of SALL4 on the Proliferation, Invasion and Apoptosis of Breast Cancer Cells

Zinc Finger Protein SALL4 Functions through an AT-Rich Motif to Regulate Gene Expression

SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and inducesAML in transgenic mice

SALL4, a Novel Oncogene Induces Myelodysplastic Syndrome and Acute Myeloid Leukemia Via Wnt/β-Catenin Pathway.

Inhibition of SALL4 Reduces Tumorigenicity Involving Epithelial-Mesenchymal Transition Via Wnt/β-catenin Pathway in Esophageal Squamous Cell Carcinoma

Upregulation of SALL4 by EGFR activation regulates the stemness of CD44-positive lung cancer

Dissecting the role of SALL4, a newly identified stem cell factor, in chronic myelogenous leukemia

The Expression of SALL4 in Patients with Gliomas: High Level of SALL4 Expression is Correlated with Poor Outcome

Exploring SALL4 as a significant prognostic marker in breast cancer and its association with progression pathways involved in cancer genesis